Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India: 1-Year follow-up [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 1, 2006, Pages 123-126

  Patel, Atul K ^a   Patel, Ketan K ^a   Patel, Jagdish K ^b   Sharma, Rakesh L ^a   Ranjan, Rajiv R ^a  

^a Infectious Diseases Clinic   (India)

^b Adit Diagnostic Center   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INDIA; LETTER; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; SEX RATIO;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INDIA; INDINAVIR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 33748117936     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000230522.86964.5d     Document Type: Letter

References (14)

1. Gulick R, Mellors J, Havlir D, et al. Indinavir, zidovudine and lamivudine: 5-year follow-up. In: The 1st IAS Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires, Argentina. Abstract No. 215.
2. Dieleman JP, Gyssens IC, van den Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV infected patients. AIDS. 1999;13:473-478.
3. Gatti G, di Biagio A, de Pascalis CR, et al. The relationship between systemic exposure to indinavir and response (virologic efficacy and renal toxicity). In: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 14-18, 2001; Chicago, IL. Abstract I-1732.
4. Solas C, Basso S, Poizot-Martin I, et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice daily regimen. J Acquir Immune Defic Syndr. 2002;29:374-377.
5. Voigt E, Wickesberg A, Wasmuth JC, et al. First-line ritonavir/indinavir 100/800mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48 week results. HIV Med. 2002;3:277-282.
6. Young B, Fischl MA, Wilson HM, et al. Open-label study of a twice-daily indinavir 800 mg/ritonavir 100 mg regimen in protease inhibitor naive HIV-infected adults. J Acquir Immune Defic Syndr. 2002;31:478-482.
7. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003;17:831-840.
8. Lamotte C, Peytavin G, Perre P, et al. Increasing adverse events with indinavir dosages and plasma concentrations in four different ritonavir- indinavir containing regimen in HIV infected patients. In: VIII Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago, IL. Abstract 738.
9. Ghosn J, Lamotte C, Ait-Mohand H, et al. Efficacy of a twice daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS. 2003;17:209-214.
10. Konopnicki D, De Wit S, Huitema A, et al. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy naive patients: comparison of 800/100mg and 400/100mg twice daily. HIV Med. 2005;6:1-6.
11. Cooper CL, Van Heeswijk RP, Gallicano K, et al. A review of low dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36:1585-1592.
12. Justesen US, Levring AM, Thomsen A, et al. Low-dose indinavir in combination with low-dose ritonavir: steady state pharmacokinetics and long-term clinical outcome follow-up. HIV Med. 2003;4(3):250-254.
13. Katlama C, Lamotte C, Hait Mohand H, et al. Ritonavir (RTV)/indinavir (IDV) (100/400 mg bid): a simple, effective and well tolerated PI containing regimen. The 1st IAS Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires, Argentina. Abstract No. 214 (Poster Presentation).
14. Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1 infected Thai patients. Antivir Ther. 2005;10:301-307.